Microbiotica
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
Microbiotica
Microbiotica is a clinical-stage biopharmaceutical company developing orally-delivered live biotherapeutic products (LBPs) for immuno-oncology and inflammatory bowel disease.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Microbiome profiling platform for identifying bacteria associated with ICI response.
Cloudflare Bot Management
Proprietary culture media and stabilization formulations
Service Requirements
Clinical trial support
Clinical trial management
Regulatory consulting
Microbiome analysis services
Support for genomic studies and genome editing
Infrastructure Requirements
Facilities for LBP manufacturing and development.
State-of-the-art laboratory facilities.
Controlled, scalable bioreactors for anaerobic fermentation, lyophilization equipment, and bespoke enteric capsules
Talent Requirements
Experts in culturing anaerobic gut bacteria
Experts in industrializable processes to grow bacteria
Talented individuals to join their team and contribute to bringing precision microbiome medicines to patients
AI Insights
Growth Trajectory
Microbiotica's advancing pipeline of LBPs, collaborations with major pharmaceutical companies like MSD, and expansion of clinical trials internationally signal strong growth potential.
Market Opportunity
Microbiotica has a strong market opportunity in developing precision microbiome medicines for ulcerative colitis and advanced melanoma, particularly in addressing the unmet needs of patients resistant to existing therapies.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats